UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended ~~September 30,~~March 31, ~~2022~~2023

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number: 001-36329

Societal CDMO, Inc.

(Exact name of registrant as specified in its charter)


Pennsylvania	26-1523233
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1 E. Uwchlan Ave, Suite 112, Exton, Pennsylvania	19341
(Address of principal executive offices)	(Zip Code)

(770) 534-8239

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of exchange on which registered
Common Stock, par value $0.01	SCTL	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 2, 2022,~~May 3, 2023, there were ~~56,700,565~~84,922,711 shares of common stock, par value $0.01 per share, outstanding.

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION		1
Item 1. Financial statements		1
Item 2. Management's discussion and analysis of financial condition and results of operations		18
Item 3. Quantitative and qualitative disclosures about market risk		25
Item 4. Controls and procedures		2625
PART II. OTHER INFORMATION		2726
Item 1. Legal proceedings		2726
Item 1A. Risk factors		2726
Item 2. Unregistered sales of equity securities and use of proceeds		2728
Item 3. Defaults upon senior securities		2728
Item 4. Mine safety disclosures		2728
Item 5. Other information		2728
Item 6. Exhibits		2729
SIGNATURES		2930

PART I. FINANCIAL INFORMATION

Item 1. Financial statements

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(Unaudited)


(amounts in thousands, except share and per share data)	September 30, 2022			December 31, 2021			March 31, 2023			December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	11,577		$	25,217		$	6,293		$	14,995
Accounts receivable, net		17,104			11,913			15,229			15,950
Contract asset		9,412			8,565
Contract assets								8,604			8,724
Inventory		9,414			8,917			11,574			10,301
Prepaid expenses and other current assets		1,987			2,917			3,337			2,848
Assets held for sale								2,801			2,768
Total current assets		49,494			57,529			47,838			55,586
Property, plant and equipment, net		49,022			51,708			50,857			50,365
Operating lease asset		5,604			5,924			5,372			5,491
Intangible assets, net		3,148			3,833			2,744			2,928
Goodwill		41,077			41,077			41,077			41,077
Other assets		2,934			246			2,050			1,996
Total assets	$	151,279		$	160,317		$	149,938		$	157,443
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$	3,057		$	2,085		$	2,392		$	1,466
Current portion of related party debt		2,039			2,039
Current portion of debt								7,840			7,577
Current portion of operating lease liability		1,075			1,055			1,086			1,079
Accrued expenses and other current liabilities		8,009			12,556			8,213			12,686
Total current liabilities		14,180			17,735			19,531			22,808
Debt, net of current portion		95,478			92,127			30,462			30,967
Related party debt, net of current portion		1,639			3,369
Operating lease liability, net of current portion		4,678			4,932			4,482			4,584
Other liabilities		70			90			39,487			39,225
Total liabilities		116,045			118,253			93,962			97,584
Commitments and contingencies (note 7)
Shareholders’ equity:
Preferred stock, $0.01 par value. 10,000,000 shares authorized, none issued or outstanding		—			—
Common stock, $0.01 par value. 95,000,000 shares authorized, 56,679,389 and 46,681,453 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		567			467
Convertible preferred stock, $0.01 par value. 10,000,000 shares authorized, 450,000 shares issued and outstanding at March 31, 2023 and December 31, 2022								4,332			4,350
Common stock, $0.01 par value. 95,000,000 shares authorized, 84,902,318 and 84,588,868 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively								849			846
Additional paid-in capital		291,133			287,351			321,114			320,298
Accumulated deficit		(256,466	)		(245,754	)		(270,319	)		(265,635	)
Total shareholders’ equity		35,234			42,064			55,976			59,859
Total liabilities and shareholders’ equity	$	151,279		$	160,317		$	149,938		$	157,443

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(Unaudited)


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
(amounts in thousands, except share and per share data)	2022			2021			2022			2021			2023			2022
Revenue	$	21,589		$	18,237		$	65,935		$	53,057		$	21,527		$	21,194
Operating expenses:
Cost of sales (excluding amortization of intangible assets)		16,055			13,160			49,639			39,831
Cost of sales														19,279			16,114
Selling, general and administrative		5,075			4,606			15,945			13,076			4,662			5,710
Amortization of intangible assets		244			135			685			835			184			221
Total operating expenses		21,374			17,901			66,269			53,742			24,125			22,045
Operating income (loss)		215			336			(334	)		(685	)
Operating loss														(2,598	)		(851	)
Interest expense		(3,544	)		(3,822	)		(10,378	)		(11,680	)		(2,145	)		(3,418	)
Gain on extinguishment of debt		—			—			—			3,352
Interest income														131			5
Loss before income taxes														(4,612	)		(4,264	)
Income tax expense														72			—
Net loss	$	(3,329	)	$	(3,486	)	$	(10,712	)	$	(9,013	)	$	(4,684	)	$	(4,264	)

Loss per share, basic and diluted	$	(0.06	)	$	(0.07	)	$	(0.19	)	$	(0.22	)	$	(0.06	)	$	(0.08	)

Weighted average shares outstanding, basic and diluted		56,666,473			51,416,388			56,539,941			40,137,069			84,799,670			56,351,178

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Statements of Shareholders’ Equity or Deficit

(Unaudited)


	Common stock				Additional paid-in			Accumulated						Convertible preferred stock					Common stock				Additional paid-in			Accumulated
(amounts in thousands, except share data)	Shares		Amount		capital			deficit			Total			Shares		Amount			Shares		Amount		capital			deficit			Total
Balance, December 31, 2021		46,681,453	$	467	$	287,351		$	(245,754	)	$	42,064
Issuance of common stock, net of costs		9,302,718		93		(109	)		—			(16	)
Stock-based compensation expense		—		—		1,479			—			1,479
Vesting of restricted stock units, net		487,695		5		(106	)		—			(101	)
Exercise of stock options		220		—		—			—			—
Net loss		—		—		—			(4,264	)		(4,264	)
Balance, March 31, 2022		56,472,086	$	565	$	288,615		$	(250,018	)	$	39,162
Issuance of common stock, net of costs		—		—		(113	)		—			(113	)
Balance, December 31, 2022															450,000	$	4,350			84,588,868	$	846	$	320,298		$	(265,635	)	$	59,859
Issuance of stock, net of costs															—		(18	)		—		—		(18	)		—			(36	)
Stock-based compensation expense		—		—		1,408			—			1,408			—		—			—		—		1,044			—			1,044
Vesting of restricted stock units, net		172,477		1		(10	)		—			(9	)		—		—			313,450		3		(210	)		—			(207	)
Net loss		—		—		—			(3,119	)		(3,119	)		—		—			—		—		—			(4,684	)		(4,684	)
Balance, June 30, 2022		56,644,563	$	566	$	289,900		$	(253,137	)	$	37,329
Issuance of common stock, net of costs		—		—		(14	)		—			(14	)
Stock-based compensation expense		—		—		1,260			—			1,260
Vesting of restricted stock units, net		34,826		1		(13	)		—			(12	)
Net loss		—		—		—			(3,329	)		(3,329	)
Balance, September 30, 2022		56,679,389	$	567	$	291,133		$	(256,466	)	$	35,234

Balance, December 31, 2020		28,601,358	$	286	$	219,998		$	(234,384	)	$	(14,100	)
Issuance of common stock, net of costs		2,202,420		22		9,318			—			9,340
Stock-based compensation expense		—		—		3,133			—			3,133
Vesting of restricted stock units, net		209,541		2		(338	)		—			(336	)
Net loss		—		—		—			(6,761	)		(6,761	)
Balance, March 31, 2021		31,013,319	$	310	$	232,111		$	(241,145	)	$	(8,724	)
Issuance of common stock, net of costs		15,333,332		153		31,950			—			32,103
Stock-based compensation expense		—		—		1,929			—			1,929
Vesting of restricted stock units, net		155,198		2		(128	)		—			(126	)
Net income		—		—		—			1,234			1,234
Balance, June 30, 2021		46,501,849	$	465	$	265,862		$	(239,911	)	$	26,416
Issuance of common stock, net of costs		—		—		20,328			—			20,328
Stock-based compensation expense		—		—		1,319			—			1,319
Vesting of restricted stock units, net		112,606		1		(94	)		—			(93	)
Exercise of stock options		80		—		—			—			—
Net loss		—		—		—			(3,486	)		(3,486	)
Balance, September 30, 2021		46,614,535	$	466	$	287,415		$	(243,397	)	$	44,484
Balance, March 31, 2023															450,000	$	4,332			84,902,318	$	849	$	321,114		$	(270,319	)	$	55,976


Balance, December 31, 2021	—	$	—	46,681,453	$	467	$	287,351		$	(245,754	)	$	42,064
Issuance of stock, net of costs	—		—	9,302,718		93		(109	)		—			(16	)
Stock-based compensation expense	—		—	—		—		1,479			—			1,479
Exercise of stock options, net	—		—	220		—		—						—
Vesting of restricted stock units, net	—		—	487,695		5		(106	)		—			(101	)
Net loss	—		—	—		—		—			(4,264	)		(4,264	)
Balance, March 31, 2022	—	$	—	56,472,086	$	565	$	288,615		$	(250,018	)	$	39,162

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(Unaudited)


	Nine months ended September 30,						Three months ended March 31,
(amounts in thousands)	2022			2021			2023			2022
Cash flows from operating activities:
Net loss	$	(10,712	)	$	(9,013	)	$	(4,684	)	$	(4,264	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		4,147			6,381			1,044			1,479
Non-cash interest expense		3,778			4,531			314			1,257
Depreciation expense		5,516			4,803			1,905			1,792
Amortization of intangible assets		685			835			184			221
Gain on extinguishment of debt		—			(3,352	)
Deferred income tax expense								72			—
Changes in operating assets and liabilities:
Accounts receivable		(5,191	)		(3,801	)		721			(2,211	)
Contract asset		(847	)		521
Contract assets								120			(369	)
Inventory		(497	)		2,857			(1,273	)		(553	)
Prepaid expenses and other assets		1,221			491			(416	)		1,134
Accrued interest		(2,473	)		48			(22	)		(2,274	)
Accrued payroll		(2,005	)		2,507
Accounts payable, accrued expenses and other liabilities		740			(393	)		(818	)		(4,292	)
Net cash (used in) provided by operating activities		(5,638	)		6,415
Net cash used in operating activities								(2,853	)		(8,080	)
Cash flows from investing activities:
Acquisition of IriSys, net of cash required		—			(24,006	)
Purchases of property and equipment		(5,615	)		(2,765	)		(3,376	)		(1,708	)
Net cash used in investing activities		(5,615	)		(26,771	)		(3,376	)		(1,708	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of costs		(143	)		32,103
Payment of costs for issuance of stock								(553	)		(16	)
Payment of debt principal		(2,039	)		(10,100	)		(461	)		—
Payment of financing costs		(83	)		(1,362	)		(1,252	)		(36	)
Net payments related to vesting of restricted stock units		(122	)		(555	)		(207	)		(101	)
Net cash (used in) provided by financing activities		(2,387	)		20,086
Net cash used in financing activities								(2,473	)		(153	)
Net decrease in cash and cash equivalents		(13,640	)		(270	)		(8,702	)		(9,941	)
Cash and cash equivalents, beginning of period		25,217			23,760			14,995			25,217
Cash and cash equivalents, end of period	$	11,577		$	23,490		$	6,293		$	15,276
Supplemental disclosures of cash flow information:
Cash paid for interest	$	10,081		$	7,462		$	2,144		$	4,676
Purchases of property, plant and equipment included in accrued expenses and accounts payable		919			158			405			774
Deferred financing costs included in accrued expenses and accounts payable		35			-
Assets reclassified as held for sale		2,659			-
Fair value of shares issuable to former equity holders of IriSys		—			20,931
Fair value of note issued to former equity holders of IriSys		—			5,240
Issuance of common stock to reduce debt principal and accrued exit fees		—			6,060
Issuance of common stock to settle interest obligations		—			3,211
Deferred financing costs included in accounts payable and accrued expenses								240			—
Offering costs included in accounts payable and accrued expenses								10			—

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Notes to consolidated financial statements

(amounts in thousands, except share and per share data)

(Unaudited)

(1) Background

Societal CDMO, Inc. (the “Company”) was incorporated in the Commonwealth of Pennsylvania on November 15, 2007 as Recro Pharma, Inc. Effective March 21, 2022, Recro Pharma, Inc changed its name to Societal CDMO, Inc. to reflect the corporate transformation that had taken place primarily as a result of its acquisition and successful integration of IriSys, LLC (“IriSys”) into the organization.. The Company is a bi-coastal contract development and manufacturing organization with capabilities spanning pre-investigational new drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus ~~in the area of~~on small molecules. With an expertise in solving complex manufacturing problems, the Company provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. ~~The Company has determined that it operates in a~~ ~~single~~ ~~segment.~~

The Company has incurred net losses since inception and has an accumulated deficit of $~~256,466~~270,319 as of ~~September 30, 2022,~~March 31, 2023, which is primarily related to the activities of its former research and development business, ~~that~~which was spun-out in 2019. The Company’s future operations are highly dependent on the profitability of its development and manufacturing operations. Management believes that it is probable that the Company will be able to meet its obligations as they become due within at least one year after the date financial statements included herein are issued.

(2) Summary of significant accounting principles

Basis of presentation and principles of consolidation

The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. In accordance with Securities and Exchange ~~Commission's~~Commission’s (“SEC”) rules for interim financial statements, certain information required by U.S. GAAP may be condensed or omitted. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year. The Company has determined that it operates in a single segment.

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022.

Use of estimates

The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.

~~Business combinations~~

The Company measures the purchase price paid for acquired companies based on fair value and allocates that purchase price to the assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from the acquired companies and expectations of future cash flows. Costs associated with business combinations are expensed as incurred and classified as selling, general and administrative expenses.

Cash and cash equivalents

Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value due to changes in interest rates.

Accounts receivable, net

Accounts receivable generally represent amounts billed for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for credit losses, if necessary. We apply judgment in assessing the ultimate realization of our receivables, and we estimate an allowance for credit losses based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. The allowance for credit losses was not material as of the balance sheet dates presented.

Inventory

Inventory is stated at the lower of cost or net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Items are issued out of inventory using the first-in, first-out method.

Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.

Property, plant and equipment, net

Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture, office and computer equipment; sixto ten years for manufacturing equipment; 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. The Company reviews the carrying value of property, plant and equipment for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of individual assets or asset groups may not be recoverable.

The Company considers assets to be held for sale when (i) management commits to a plan to sell the asset; (ii) the asset is available for immediate sale in its present condition; (iii) the asset is actively being marketed for sale at a price that is reasonable given the estimate of current market value; and (iv) the sale is probable and will be completed within one year. Upon designation of an asset as held for sale, the Company records the asset’s value at the lower of its carrying value plus selling costs or its estimated net realizable value.

Goodwill and intangible assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company in a business combination. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist.

The impairment analysis for goodwill consists of an optional qualitative assessment potentially followed by a quantitative analysis. If the Company determines that the carrying value of its reporting unit exceeds its fair value, an impairment charge is recorded for the excess.

The Company performs its annual goodwill impairment test as of November 30th, or whenever an event or change in circumstance occurs that would require reassessment of the impairment of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance, actual and anticipated changes in industry and market conditions, and competitive environments. As a result of the most recent annual goodwill impairment test, the Company determined that there was no impairment of goodwill.

Definite-lived intangible assets are amortized on a straight-line basis over their estimated useful ~~lives.~~life. The Company is required to review the carrying value of definite-lived intangible assets for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable.

Contingencies

The ~~Company's~~Company’s business exposes it to various contingencies including compliance with regulations, legal exposures and other matters. Loss contingencies are reflected in the financial statements based on ~~management's~~management’s assessments of their expected outcome or resolution:

•

They are recognized as liabilities on the balance sheet if the potential loss is probable and the amount can be reasonably estimated.

•

They are disclosed if the potential loss is material and considered at least reasonably possible.

Significant judgment is required to determine probability and whether the amount can be reasonably estimated. Due to uncertainties related to these matters, accruals are based only on the information available at the time. As additional information becomes available, the Company reassesses potential liabilities and may revise previous estimates.

Revenue recognition

The Company generates revenues from manufacturing, packaging ~~research~~ and development and related services for multiple pharmaceutical companies.

Manufacturing

Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include variable consideration such as pricing and volume-based adjustments.

Profit-sharing

In addition to manufacturing and packaging revenue, certain ~~customer~~customers who use our technologies are subject to agreements ~~may have~~that provide us intellectual property sales-based profit-sharing and/or royalties consideration, collectively referred to as profit-sharing, computed on the net product sales of the commercial partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. ~~For~~The Company has determined that, in its arrangements, ~~that include sales-based profit-sharing where~~ the license for intellectual property is ~~deemed to be~~not the predominant item to which the profit-sharing relates, the Company recognizes revenue when the related sales occur by the commercial partner. For arrangements that include sales-based profit-sharing where the license for intellectual property is not deemed to be the predominant item to which the profit-sharing relates,so the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by the Company’s commercial partners, which are outside of the Company’s control. Factors causing price adjustments by the Company’s commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing.

~~Research and development~~Development

~~Research and development~~Development revenue includes services associated with formulation, process development, clinical ~~trials~~trial materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms.

In contracts that specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within the Company’s control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received.

In contracts that require revenue recognition over time, the Company utilizes input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications, and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by the Company’s services and can make changes to its process or specifications upon request.

Contract assets represent revenue recognized for performance obligations completed or in process before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. Contract liabilities represent payments received from customers prior to the completion of associated performance obligations.

Concentration of credit risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity.

The Company’s accounts receivable balances are primarily concentrated among three ~~customers.~~customers, with balances in the aggregate accounting for 86% of the balance as of March 31, 2023. If any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition.

The Company is dependent on its relationships with a small number of commercial partners. The ~~Company's~~ Company’s three largest customers generated 6484% of revenues for the three months ended March 31, 2023, and 6978% of its revenues for the three ~~and nine~~ months ended ~~September 30, 2022, respectively.~~March 31, 2022.

Stock-based compensation expense

The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur.

Determining the appropriate fair value of stock options requires the use of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards.

The expected life of stock options was estimated using the “simplified method,” which is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option.

Upon exercise of stock options or vesting of restricted stock units, the holder may elect to cover tax withholdings by forfeiting shares of an equivalent value. In such cases, the Company issues net new shares to the holder, pays the tax withholding on behalf of the participant and presents the payment similar to a capital distribution: a reduction to additional paid-in-capital and a financing cash outflow in the consolidated financial statements.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. ~~A valuation allowance is recorded to~~

In assessing the ~~extent~~realizability of net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. A full valuation allowance was recorded as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021.~~2022.

Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.

Leases

The Company determines under U.S. GAAP if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Options to extend the lease are included in the lease term if the options are reasonably certain to be exercised. Operating lease expense is recognized on a straight-line basis over the lease term. In a sale-leaseback transaction, the Company determines under U.S. GAAP if the transaction meets the requirements of a sale and purchase. If the Company determines that it did not relinquish control of the assets to the buyer-lessor, it does not qualify for sale-leaseback accounting.

Operating lease balances are presented as separate captions on the balance sheets. Finance lease assets are included in property, plant and equipment. Finance lease liabilities are included in ~~debt.~~other liabilities.

Income or loss per share

Net loss per common share is computed using the two-class method required due to the participating nature of the Series A Convertible Preferred Stock (as defined and discussed in note 10) given the rights to participate in dividends if declared on common stock. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders. In addition, as these securities are participating securities, the Company is required to calculate diluted net income or loss per share under the if-converted and treasury stock method in addition to the two-class method and utilize the most dilutive result. In periods where there is a net loss, no allocation of undistributed net loss to the Series A Convertible Preferred stockholders is performed as the holders of these securities are not contractually obligated to participate in the Company’s losses.

Basic income or loss per share is determined by dividing net income or loss (the numerator) by the weighted average common shares outstanding during the period (the denominator).

To calculate diluted income or loss per share, the numerator and denominator are adjusted to eliminate the income or loss and the dilutive effects on shares, respectively, caused by outstanding common stock options, warrants and unvested restricted stock units, using the treasury stock method, if the inclusion of such instruments would be dilutive.

For all periods presented, the Company incurred a net loss. In periods of net loss, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share.

The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022
Restricted stock units		1,717,982		708,965		1,461,529		377,437		1,054,173		739,148
Stock options		8,020,457		4,965,826		7,331,963		4,496,878		6,348,587		6,860,892
Warrants		348,664		348,664		348,664		348,664		402,126		348,664

Amounts in the table above reflect the common stock equivalents of the noted instruments.

~~Recent accounting pronouncements~~

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). This ASU provides temporary optional expedients and exceptions to the guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate and other interbank offered rates to alternative reference rates. In January 2021, the FASB issued ASU 2021-01, which refines the scope of Topic 848 and clarifies some of its guidance as part of the FASB’s monitoring of global reference rate activities. The new guidance was effective upon issuance, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

(3) Inventory

The following table presents the components of inventory:


	September 30, 2022		December 31, 2021		March 31, 2023		December 31, 2022
Raw materials	$	3,563	$	3,038	$	6,504	$	4,318
Work in process		3,862		3,363		3,826		3,689
Finished goods		1,989		2,516		1,244		2,294
Inventory	$	9,414	$	8,917	$	11,574	$	10,301

(4) Intangible assets, net

The following table presents the components of other intangible assets:


	March 31, 2023						December 31, 2022
	Gross value		Accumulated amortization		Carrying value		Gross value		Accumulated amortization		Carrying value
Customer relationships	$	18,900	$	16,309	$	2,591	$	18,900	$	16,188	$	2,712
Backlog		460		307		153		460		261		199
Trademarks and tradenames		310		310		—		310		293		17
Total	$	19,670	$	16,926	$	2,744	$	19,670	$	16,742	$	2,928

The following table presents estimated future amortization of other intangible assets:


Twelve months ending March 31,
2023	$	670
2024		455
2025		486
2026		486
2027		486
Thereafter		161
Total	$	2,744

~~(4)~~(5) Property, plant and equipment, net

The following table presents the components of property, plant and equipment:


	September 30, 2022			December 31, 2021			March 31, 2023			December 31, 2022
Land	$	604		$	3,263		$	604		$	604
Building and improvements		22,751			22,717			22,781			22,751
Furniture, office and computer equipment		6,272			6,213			6,573			6,388
Manufacturing equipment		57,577			49,687			59,332			58,039
Construction in progress		4,362			6,856
Construction in process								7,913			7,024
Property, plant and equipment, gross		91,566			88,736			97,203			94,806
Less: accumulated depreciation		(42,544	)		(37,028	)		(46,346	)		(44,441	)
Property, plant and equipment, net	$	49,022		$	51,708		$	50,857		$	50,365

Interest expense capitalized to construction in ~~progress~~process was $~~419~~206 and $55268 for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and $982~~ ~~and $120~~ ~~for the nine months ended September 30, 2022 and 2021,~~ respectively.

~~During the third quarter,~~In September 2022, the Company signed a sales and purchase agreement to sell approximately 121 acres of land adjacent to its Gainesville, Georgia manufacturing campus for expected proceeds of $9,075. The land was determined to be held for sale at September 30, 2022 and reclassified at cost to other current assets with a carrying value of $2,659. Selling costs of $142 have also been capitalized into the asset. The sale of the land is subject to customary closing conditions for transactions of this type, including completion of title and environmental due diligence and receipt of certain zoning approvals and permits, which ~~remain~~remained to be satisfied at ~~September 30, 2022.~~March 31, 2023.

~~(5)~~ I~~ntangible assets, net~~

~~The following table presents the components of other intangible assets:~~

September 30, 2022

December 31, 2021

Gross value

Accumulated amortization

Carrying value

Gross value

Accumulated amortization

Carrying value

Customer relationships
$
18,900

$
16,066

$
2,834

$
18,900

$
15,685

$
3,215

Backlog

460

215

245

460

73

387

Trademarks and tradenames

310

241

69

310

79

231

Total
$
19,670

$
16,522

$
3,148

$
19,670

$
15,837

$
3,833

~~The following table presents estimated future amortization of other intangible assets:~~

Twelve months ending September 30,

2023
$
739

2024

547

2025

486

2026

486

2027

486

Thereafter

404

Total
$
3,148

(6) Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:


	September 30, 2022		December 31, 2021		March 31, 2023		December 31, 2022
Accrued transaction costs					$	2,046	$	3,653
Contract liabilities (see note 11)						1,757		2,211
Payroll and related costs	$	3,712	$	5,717		1,576		4,276
Current portion of contract liabilities (see note 10)		2,372		2,308
Property, plant and equipment		320		663		247		934
Professional and consulting fees		521		552		213		356
Accrued interest		32		2,505		205		227
Other		1,052		811		2,169		1,029
Total	$	8,009	$	12,556	$	8,213	$	12,686

Accrued transaction costs include costs incurred related to the refinancing completed in December 2022 which included the sale and subsequent leaseback of the Company’s commercial manufacturing campus located in Gainesville, Georgia (see note 9), the issuance of common and preferred stock, a borrowing of $36,900 under a new term loan with Royal Bank of Canada (see note 8) and a one-time cash transaction bonus to certain executive officers and employees.

(7) Commitments and contingencies

Litigation

The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations.

On May 31, 2018, a securities class action lawsuit (the “Securities Litigation”) was filed against the Company and certain of its officers and directors (collectively, the “Defendants”) in the U.S. District Court for the Eastern District of Pennsylvania (the “Court”) (Case No. 2:18-cv-02279-MMB) that purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning the New Drug Application (“NDA”) for IV meloxicam. The complaint sought unspecified damages, interest, attorneys’ fees and other costs. On March 24, 2022, the plaintiff informed the Court that the parties had reached an agreement-in-principle to settle the Securities Litigation and requested that the Court stay all deadlines. On May 10, 2022, the plaintiff filed an unopposed motion for preliminary approval of the class action settlement. The Court entered an order preliminarily approving the settlement and providing for notice on May 12, 2022. A hearing for the final approval of the settlement occurred on October 26, 2022, and the parties are awaiting a decision.

In connection with the separation of the Company's former acute care research and development business into a new standalone entity named Baudax Bio, Inc. (“Baudax Bio”), Baudax Bio accepted assignment by the Company of all of its obligations in connection with the Securities Litigation and agreed to indemnify it for all liabilities related to the Securities Litigation.

On July 2, 2022, a product liability lawsuit was filed against the Company and various other defendants in the State Court of Cobb County, Georgia that claimed injuries and damages caused by Plaintiff Jakob Cuble’s alleged ingestion of, among other things, Focalin XR. The complaint ~~seeks~~sought compensatory and punitive damages. On ~~July 7, 2022, and prior to~~April 14, 2023, Plaintiff's counsel withdrew the Company being served with the Complaint, a co-defendant removed the matter to the United States District Court for the Northern District of Georgia, Atlanta Division. The Company filed its responsive pleading on August 2, 2022. In September 2022, the case was remanded to the State Court of Cobb County, Georgia, where it presently pends. The Company believes that the lawsuit is without merit and intends to vigorously defend against it.case.

Purchase commitments

As of ~~September 30, 2022,~~March 31, 2023, the Company had outstanding cancelable and non-cancelable purchase commitments in the aggregate amount of $~~12,371~~9,933 related to inventory, capital expenditures and other goods and services.

Employment agreements and certain other contingencies

The Company has entered into employment agreements with each of its ~~named~~ executive officers that provide for, among other things, severance commitments of up to $~~1,303~~1,393 should the Company terminate the ~~named~~ executive officers for convenience or if certain events occur following a change in control. In addition, the Company is subject to other contingencies of up to $~~3,772~~3,944 in the aggregate if certain events occur following a change in control.

(8) Debt

The following table presents the components and classification of debt:


	September 30, 2022			December 31, 2021			March 31, 2023			December 31, 2022
Debt principal:
Terms loans under Credit Agreement	$	100,000		$	100,000
Term loan under Credit Agreement							$	36,439		$	36,900
Note with former equity holder of IriSys		4,078			6,117			4,078			4,078
Other		339			339			339			339
Debt principal		104,417			106,456			40,856			41,317
Debt adjustments:
Unamortized deferred issuance costs		(5,687	)		(8,896	)		(2,325	)		(2,476	)
Exit fee accretion		793			669
Unamortized original discount		(367	)		(694	)		(229	)		(297	)
Carrying value of debt	$	99,156		$	97,535		$	38,302		$	38,544

Current portion of related party debt	$	2,039		$	2,039
Current portion of debt							$	7,840		$	7,577
Debt, net of current portion		95,478			92,127			30,462			30,967
Related party debt, net of current portion		1,639			3,369
Carrying value of debt	$	99,156		$	97,535		$	38,302		$	38,544

The following table presents the future maturity of debt principal:


Twelve months ending September 30,
2023	$	2,039
Twelve months ending March 31,
2024		102,048	$	7,840
2025		30		5,060
2026		37		27,673
2027		44		41
2028				49
Thereafter		219		193
Total debt principal	$	104,417	$	40,856

Term ~~loans~~loan under Credit Agreement

The Company is currently party to a credit agreement ~~(the~~(as amended from time to time, the “Credit Agreement”) with ~~Athyrium Opportunities III Acquisition LP (“Athyrium”).~~Royal Bank of Canada. The Credit Agreement has been fully drawn in the form of a term loan of $~~48,000~~36,900. The outstanding principal amount will be repaid in quarterly amounts totaling $2,076, $2,998 and $1,845 during the twelve months ending March 31, 2024, 2025 and 2026, respectively. The final payment of all remaining outstanding principal is due on December 16, 2025. If the Company completes a sale of certain real property by December 14, 2023 and makes the $10,000 principal repayment disclosed below, the quarterly principal payments will be reduced proportionately to the reduction in principal.

Subject to certain exceptions, the Company is required to make mandatory prepayments with the cash proceeds received in respect of asset sales, extraordinary receipts and debt issuances, upon a change of control and specified other events. Additionally, the Company is obligated to repay $10,000 of ~~term A loans and $52,000~~principal by December 14, 2023, upon the sale of ~~term B loans, all of which mature on~~ certain real property adjacent to its Gainesville, Georgia manufacturing campus (see note 5). If that property is not sold by December ~~31,~~14, 2023,.

~~The term loans under the Credit Agreement bear a rate of~~ ~~interest equal to the three-month LIBOR rate, with a~~ 1~~% floor, plus~~ ~~8.25% per annum. The term loans require~~ the Company will be required to pay a 1~~% exit~~ fee ~~on all repayments. At September 30, 2022, the aggregate exit fee payable was~~of $~~1,000~~369, and increase each of its quarterly principal payments by $231 until that property is sold and the ~~cumulative exit fee accreted was~~ $~~793~~10,000~~. The exit fees are being accreted to~~ principal payment is made. Because the Company concluded that the sale of the property is probable as of March 31, 2023, an additional $3,726 of debt principal has been presented as current, representing the carrying ~~amount~~value of the ~~debt using~~current asset held for sale plus the ~~effective interest method~~$925 excess of the principal payment over the ~~term of~~expected proceeds from the ~~loan. In addition,~~ ~~if the Company makes any prepayments prior to maturity, the Company would be subject to prepayment premiums on the term B loans, as a percentage of the amount repaid, of~~ ~~2.5~~%.asset.

The Credit Agreement ~~contains~~also includes certain ~~usual and customary affirmative and negative covenants, as well as~~ financial covenants that the Company will need to satisfy on a ~~monthly and~~ quarterly basis, ~~including~~including: (i) maintaining a ~~permitted~~ net leverage ratio ~~(which is~~less than 3.75:1.00, stepping down to 2.75:1.00 at the ~~Company’s indebtedness under the Credit Agreement, net~~end of 2023; (ii) maintaining a fixed charge coverage ratio greater than 1.15:1.00; and (iii) maintaining no less than $4,000 cash and cash equivalents ~~divided~~on hand, stepping up to $5,000 by ~~EBITDA, each as defined in~~ the ~~Credit Agreement) and liquidity amount.~~end of 2024. As of ~~September 30, 2022,~~March 31, 2023, the Company was in compliance with its covenants under the Credit Agreement.

The Credit Agreement was amended in March 2023 to clarify the terms and definitions of the aforementioned financial covenants.

In connection with the Credit Agreement, the Company ~~issued warrants to each of Athyrium and its affiliate, Athyrium Opportunities II Acquisition LP (“Athyrium II”), to purchase an aggregate of~~ ~~348,664~~ ~~shares of the Company’s common stock with an exercise price of $1.73~~ ~~per share. See note 9 for additional information. The warrants are exercisable through~~ ~~November 17, 2024~~.

~~In connection with the Credit Agreement and amendments made to it over the years, the Company~~ has paid financing ~~costs, has incurred costs to record and subsequently to adjust the value of the warrants described above and has been accreting the exit fee described above.~~costs. These costs are being recognized in interest expense using the effective interest method over the term of the Credit Agreement, resulting in non-cash interest expense of $~~1,163~~ ~~and $1,389~~236 for the three months ended ~~September 30, 2022 and 2021, respectively, and $~~March 31, 2023.

The Credit Agreement bears ~~3,451~~interest at a floating rate equal to the three-month term Secured Overnight Financing Rate, or SOFR, with an initial floor of ~~and $~~1.00~~4,469~~%, plus an applicable margin that is equal to 4.50% per annum for the ~~nine months ended September 30, 2022~~first year, 5.00% for the second year and ~~2021, respectively.~~

5.50% for the third year, with quarterly interest payments due until maturity.At ~~September 30, 2022,~~March 31, 2023, the overall effective interest rate, including cash paid for interest and non-cash interest expense, was ~~15.1~~12.1%.

Historical term loans with Athyrium

The Company was previously party to a credit agreement with Athyrium Opportunities III Acquisition LP (“Athyrium Credit Agreement”). The Athyrium Credit Agreement included $100,000 of term loans at an interest rate equal to the three-month LIBOR rate plus 8.25% per annum.

The Athyrium Credit Agreement was amended numerous times with the Company paying financing costs and accreting an exit fee. These costs were recognized in interest expense using the effective interest method, resulting in non-cash interest expense of $1,137 for the three months ended March 31, 2022. The Company repaid the term loans in full using the proceeds from the new Credit Agreement, the sale-leaseback transaction (see note 9) and the issuance of preferred and common stock (see note 10) in December 2022.

Note with former equity holder of IriSys

In connection with the acquisition of IriSys, LLC (“IriSys”), the Company issued a subordinated promissory note to a former equity holder of IriSys in the aggregate principal amount of $6,117 (the “Note”). The Note is unsecured, has a three-year term, and bears interest at a rate of 6% per annum. The Note must be repaid in three equal annual installments through its maturity date, August 13, 2024. The Note may be prepaid in whole or in part at any time prior to the maturity date. The Note is expressly subordinated in right of payment and priority to the term ~~loans~~loan under the Credit ~~Agreement with Athyrium.~~Agreement.

The Note was initially recognized at fair value as part of the consideration paid for the acquisition of IriSys, resulting in an original discount recognized of $877 that is being recognized as interest expense using the effective interest method over the term of the Note. At ~~September 30, 2022,~~March 31, 2023, the overall effective interest rate, including the amortization of the original discount, was 13.0%.

Since the acquisition of IriSys, we believe that the note holder has held a combination of direct beneficial interests and significant influence over at least 10% of the Company's outstanding common stock. As a result, the Company has presented the note holder as a related party.

The Company ~~paid interest of $367~~ ~~to the note holder during the three and nine months ended September 30, 2022 and~~ has accrued interest of $32154 through ~~September 30, 2022~~March 31, 2023 that will become payable to the former equity holder of IriSys on August 13, 2023.

(9)Other liabilities

~~In connection with the acquisition of IriSys, the Company assumed~~At March 31, 2023, other liabilities include a ~~loan with a principal amount~~sale-leaseback liability of $~~339~~38,382 and other liabilities of $1,105.

Sale-leaseback liability

In December 2022, the Company concurrently entered into sale and lease agreements with Tenet Equity Funding SPE Gainesville, LLC (“Tenet”) related to its commercial manufacturing campus in Gainesville, Georgia. The selling price was $39,000, of which $1,750 was retained by Tenet as a lease deposit and classified within other assets, resulting in cash proceeds to the Company of $37,250 in 2022. The lease is for an initial term of 20 years with four renewal options of ten years each. Rent under the lease will be payable monthly at a rate of $3,510 per year, increasing annually by 3%, except for the first year where annual base rent will increase by the change in the consumer price index, not to exceed 5%, if greater. The Company is responsible for the payment of all operating expenses, property taxes and insurance for the property. Pursuant to the terms of the lease, the Company will have a purchase option every ten years and a right of first offer and a right of first refusal to purchase the property should the buyer-lessor intend to sell the property to a third party.

The Company determined that it did not relinquish control of the assets to the buyer-lessor. Therefore, the assets were not derecognized, and the selling price was recorded as a financial liability. As of March 31, 2023, the Company has recognized a liability of $38,382, that is net of $847 of deferred financing costs. The Company will recognize interest expense at a 10.95% imputed rate of interest over a term of 20 years. The deferred financing costs will also be amortized and recognized as interest expense using the effective interest method over the term of the lease. The gross liability balance will increase through 2034, at which point it will decrease through the end of lease term on December 31, 2042.

~~(9)~~(10) Shareholders’ equity or deficit

~~Capital raises~~

~~The following table presents the Company’s capital raises since its initial public offering in March 2014:~~Convertible preferred stock

Date or period

Shares of common stock issued

Gross proceeds

Offering expenses

Net proceeds

Initial public offering
March 12, 2014

4,312,500

$
34,500

$
(4,244
)

$
30,256

Private placement
July 7, 2015

1,379,311

16,000

(1,188
)

14,812

Underwritten public offering
August 19, 2016

1,986,666

14,900

(1,533
)

13,367

Underwritten public offering
December 16, 2016

6,670,000

40,020

(3,132
)

36,888

2018 common stock purchase agreement with Aspire Capital
Year ended December 31, 2018

1,950,000

16,999

—

16,999

2019 common stock purchase agreement with Aspire Capital
Fourth quarter 2020

4,690,972

11,172

(78
)

11,094

Share issuance agreement for amendment 5 to Credit Agreement
February 2021

2,202,420

9,338

(20
)

9,318

Underwritten public offering
May 12, 2021

15,333,332

34,500

(2,397
)

32,103

Issuance of shares for IriSys acquisition
February 2022

9,302,718

20,931

(619
)

20,312

~~Shares issued~~

~~As part of the consideration paid for the acquisition of IriSys,~~In December 2022, the Company issued ~~9,302,718~~450,000 shares of ~~its~~Series A Convertible Preferred Stock for proceeds of $11.00 per share. Each share is convertible into ten shares of common stock ~~on February 23, 2022.~~

~~Aspire common stock purchase agreement~~

The Company is currently party to an amended common stock purchase agreement with Aspire Capital Fund LLC (“Aspire Capital”) originally entered into during 2019, and most recently amended in February 2021 (as amended, the “2019 Common Stock Purchase Agreement”). The 2019 Common Stock Purchase Agreement provides that,automatically upon ~~the terms and subject to the conditions and limitations set forth in the agreement, Aspire Capital is committed to purchase, at~~approval by the Company’s ~~sole election, up~~shareholders to ~~an aggregate value~~increase the number of $~~41,172~~ inauthorized shares of common stock. AsIf the approval is not obtained by June 30, 2023, the conversion rate will be immediately increased by 10% and annually thereafter until approval has been obtained. Shares of ~~September 30, 2022, there is availability~~Series A Convertible Preferred Stock feature a liquidation preference over common shares, have no voting rights and are entitled to ~~issue up to $30,000~~ or ~~6,199,299~~receive dividends equally with shares of common stock ~~under the 2019 Common Stock Purchase Agreement.~~on an as-if-converted basis.

Warrants

At ~~September 30, 2022,~~March 31, 2023, warrants to purchase ~~348,664~~402,126 shares of common stock were outstanding. The warrants were originally issued to Athyrium in connection with the Athyrium Credit Agreement, are ~~held by Athyrium,~~ equity-classified, exercisable at $~~1.73~~1.50 per share and expire in November 2024. ~~See note 8 for additional details.~~

~~(10)~~(11) Revenue recognition

The following table presents changes in contract assets and liabilities:

Contract assets

Contract liabilities

Balance at December 31, 2021
$
8,565

$
2,308

Changes to the beginning balance of contract assets arising from:

Reclassification to receivables as a result of rights to consideration becoming unconditional

(11,224
)

—

Reduction to offset within net contract asset due to recognition of revenue

1,017

—

Changes in estimate

1,659

—

Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates

9,395

—

Changes to contract liabilities:

Amounts billed in advance of contract performance

—

4,921

Revenue recognized

—

(4,857
)
Balance at September 30, 2022
$
9,412

$
2,372


	Contract assets			Contract liabilities
Balance at December 31, 2022	$	8,724		$	(2,211	)
Changes to the beginning balance arising from:
Reclassification to receivables as the result of rights to consideration becoming unconditional		(6,519	)		—
Reclassification to revenue as the result of performance obligations satisfied		344			1,237
Changes in estimate		768			—
Net change to contract balance recognized since beginning of period due to recognition of revenue, amounts billed and changes in estimate		5,287			(783	)
Balance at March 31, 2023	$	8,604		$	(1,757	)

Contract assets and contract liabilities are reported at the contract level. Contracts with multiple performance obligation are reported as a net contract asset or contract liability on the consolidated balance sheet. The reclassification to revenue appearing in the contract assets column results from the recognition of revenue on contract liabilities that are presented as a net contract asset at the beginning of the year.

The following table disaggregates revenue by timing of revenue recognition:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022
Point in time	$	15,565	$	14,361	$	51,851	$	45,947	$	16,813	$	16,880
Over time		6,024		3,876		14,084		7,110		4,714		4,314
Total	$	21,589	$	18,237	$	65,935	$	53,057	$	21,527	$	21,194

The Company’s payment terms for manufacturing revenue and development services are typically 30 to 45 days. Profit-sharing revenue is recorded to accounts receivable in the quarter that the product is sold by the commercial partner upon reporting from the commercial partner and payment terms are generally 45 days after quarter end.

~~(11)~~(12) Stock-based compensation

In October 2013, the Company established an equity incentive plan that has been subsequently amended and restated to become the 2018 Amended and Restated Equity Incentive Plan (the “A&R Plan”). At ~~September 30, 2022,~~March 31, 2023, a total of ~~288,667~~4,411,012 shares were available for future grants under the A&R Plan. On December 1st of each year, pursuant to an “evergreen” provision of the A&R Plan, the number of shares available under the A&R Plan may be increased by the board of directors by an amount equal to 5% of the outstanding common stock on December 1st of that year.

Stock options

Stock options are exercisable generally for a period of ten years from the date of grant and generally vest over four years.

The following table presents information about the fair value of stock options granted:


	Nine months ended September 30,				Three months ended March 31,
	2022		2021		2023			2022
Weighted average grant date fair value	$	1.02	$	1.78	$	0.84		$	1.16
Assumptions used to determine fair value:
Range of expected option life	5.5 - 6.0 years		5.5 - 6.0 years		6.0 years			6.0 years
Expected volatility	79 - 81%		79 - 81%			80	%		79	%
Risk-free interest rate	1.5 - 4.0%		0.7 - 1.2%		3.6%			1.5 - 2.4%
Expected dividend yield		—		—		—			—

No options were exercised in the three months ended March 31, 2023. The intrinsic value of options exercised was negligible in the ~~nine~~three months ended ~~September 30, 2022 and 2021.~~March 31, 2022.

The following table presents information about stock option balances and activity:

Number of shares

Weighted average exercise price

Aggregate intrinsic value

Weighted average remaining contractual life
Balance, December 31, 2021

5,267,567

$
6.47

5.7 years
Granted

3,984,673

1.49

Exercised

(220
)

1.71

Exchanged

(668,009
)

9.79

Forfeited or expired

(467,119
)

4.21

Balance, September 30, 2022

8,116,892

3.88

$
—

6.9 years
Exercisable

3,790,050

6.27

—

4.4 years


	Number of shares			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life
Balance, December 31, 2022		8,050,337		$	3.89			6.6 years
Granted		135,060			1.19
Forfeited or expired		(1,337,589	)		7.65
Balance, March 31, 2023		6,847,808			3.10	$	—	7.6 years
Exercisable		3,100,519			4.83		—	6.2 years

Included in the table above are ~~1,178,643~~1,023,264 options outstanding as of ~~September 30, 2022~~March 31, 2023 that were granted outside the A&R Plan. The grants were made pursuant to the inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

The table above does not include 1,455,906 options that were granted during the period as they are subject to shareholders approving an increase in the number of authorized shares of common stock at the Company's 2023 annual meeting of shareholders, subject to continued service with the Company.

Restricted stock units

Restricted stock units (“RSUs”) vest over six months to four years depending on the purpose of the award and sometimes include performance conditions in addition to service conditions. The fair value of RSUs on the date of grant is measured as the closing price of the ~~Company's~~Company’s common stock on that date. The weighted average grant-date fair value of RSUs awarded to employees was $~~1.32~~1.66 in the ~~nine~~three months ended ~~September 30, 2022 and $3.49~~ ~~in the nine months ended September 30, 2021.~~March 31, 2022. The fair value of RSUs vested was $~~774~~682 and $414 in the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and $1,868~~ ~~in the nine months ended September 30, 2021.~~respectively.

The following table presents information about recent RSU activity:


	Number of shares			Weighted average grant date fair value		Number of shares			Weighted average grant date fair value
Balance, December 31, 2021		990,065		$	3.63
Balance, December 31, 2022							2,061,866		$	1.71
Granted		1,552,590			1.32		—			—
Exchanged		167,094			0.80
Vested		(506,015	)		3.67		(498,982	)		2.31
Forfeited		(58,068	)		2.47		(2,738	)		8.32
Balance, September 30, 2022		2,145,666			1.76
Balance, March 31, 2023							1,560,146			4.28

Included in the table above are ~~110,259~~77,256 time-based RSUs outstanding at ~~September 30, 2022~~March 31, 2023 that were granted outside of the A&R Plan. The grants were made pursuant to the inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

15The table above does not include

1,793,262 time-based RSUs and 358,060 performance-based RSUs that were granted during the period as they are subject to shareholders approving an increase in the number of authorized shares of common stock at the Company's 2023 annual meeting of shareholders, subject to continued service with the Company.

Other information

The following table presents the classification of stock-based compensation expense:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022
Cost of sales	$	428	$	706	$	1,427	$	3,081	$	407	$	403
Selling, general and administrative expenses		832		613		2,720		3,300		637		1,076
Total	$	1,260	$	1,319	$	4,147	$	6,381	$	1,044	$	1,479

As of ~~September 30, 2022,~~March 31, 2023, there was $~~8,438~~6,066 of unrecognized compensation expense related to unvested options and RSUs that are expected to vest and will be expensed over a weighted average period of ~~2.3~~1.9 years.

~~On June 1, 2022,~~(13) Income taxes

The tax provision for interim periods is determined using the ~~Company issued an offer to certain employee optionholders (“Eligible Employees”), subject to specified conditions, to exchange and cancel certain options which met~~estimated annual effective consolidated tax rate, based on the defined eligibility requirements (“Eligible Options”) for a new RSU grant (“New RSUs”) (collectively known as the “Exchange Offer”). Pursuant to the Exchange Offer, 130 Eligible Employees elected to exchange Eligible Options, and the Company accepted for cancellation Eligible Options to purchase an aggregatecurrent estimate of ~~668,009~~ ~~shares of common stock, representing approximately~~ 97~~% of the total shares of common stock underlying the Eligible Options. On July 1, 2022, promptly following the expiration of the Exchange Offer, the Company granted~~ ~~167,094~~ ~~New RSUs in exchange~~full-year earnings before taxes, adjusted for the ~~cancellation~~impact of ~~the tendered Eligible Options. The New RSUs will vest in two equal annual installments.~~

~~(12) Acquisition of IriSys~~discrete quarterly items.

On The provision for income taxes was $~~August 13, 2021~~72, the Company acquired all of the units of IriSys pursuant to a unit purchase agreement. IriSys provides contract pharmaceutical product development and manufacturing services, specializing in formulation research and development and good manufacturing practices of clinical trial materials and specialty pharmaceutical products. The acquisition advances the Company’s ongoing growth strategy and leads to key synergies within business development, clinical development and commercial scale-up, as well as a strong cultural alignment and fit between the companies.

~~The following table presents unaudited supplemental pro forma financial information~~ for the three ~~and nine~~ months ended ~~September 30, 2021 as if the IriSys acquisition had occurred on January 1, 2021:~~

Three months ended September 30,

Nine months ended September 30,

2021

2021

Revenue
$
19,379

$
61,043

Net income (loss)

(3,121
)

(8,605
)

~~The pro forma financial information presented above has been prepared by combining the Company's historical results~~March 31, 2023 and the ~~historical results of IriSys and adjusting those results to eliminate historical transaction costs and to reflect~~effective tax rate was approximately (2)% for the ~~effects of~~same period. There was no provision for income taxes for the ~~acquisition as if they occurred on January 1, 2021.~~three months ended March 31, 2022. The effects of the acquisition on the historical pro forma financial information include additional depreciation and amortization expense from the increase of asset carrying values to fair value, the adoption of new accounting standards, additional interest expense from the issuance of the subordinated promissory note and the elimination of interest expense related to indebtedness of IriSys priorchange in effective tax rate was due to the ~~acquisition. These results do not purport to be indicative~~utilization of all net operating loss carryforwards without limitations during 2022 in connection with the results of operations which actually would have resulted had the acquisitions occurred on the date indicated above, or that may result in the future, and do not reflect potential synergies or additional costs following the acquisition.sale-leaseback transaction (see note 9).

~~(13)~~(14) Fair value of financial instruments

The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments and certain warrants. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows:

•

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;

•

Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and

•

Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Items measured at fair value on a recurring basis

Cash equivalents of $~~10,794~~5,394 at ~~September 30, 2022~~March 31, 2023 and $~~15,247~~6,034 at December 31, ~~2021~~2022 consisted entirely of money market mutual funds whose fair value were determined using Level 1 measurements.

Fair value disclosures

The Company follows the disclosure provisions of FASB ASC Topic 825, “Financial Instruments” (ASC 825), for disclosure purposes for financial assets and financial liabilities that are not measured at fair value. As of ~~September 30, 2022,~~March 31, 2023, the financial assets and liabilities recorded on the consolidated balance sheets that are not measured at fair value on a recurring basis include accounts receivable, accounts payable and accrued expenses. The carrying values of these financial assets and liabilities approximate fair value due to their short-term nature.

The fair value of long-term debt, where a quoted market price is not available, is evaluated based on, among other factors, interest rates currently available to the Company for debt with similar terms, remaining payments and considerations of the Company’s creditworthiness. The Company determined that the recorded book value of its debt, a level 2 measurement, approximated fair value at ~~September 30, 2022~~March 31, 2023 due to the recent issuances ~~and amendment~~ of those instruments and taking into consideration ~~management's~~management’s current evaluation of market conditions.

~~(14)~~(15) Leases

The Company is party to two operating leases for development facilities in California and Georgia that end in 2031and 2025, respectively, as well as other immaterial operating leases for office space, storage and office equipment. The development facility leases each include options to extend, none of which are included in the lease terms. Short-term and variable lease costs were not material for the periods presented. The development facility leases do not provide an implicit rate, so the Company uses its incremental borrowing rate to discount the lease liabilities.

Undiscounted future lease payments for the two development leases, which were the only material noncancelable leases at ~~September 30, 2022,~~March 31, 2023, were as follows:


Twelve months ended September 30,
2023	$	1,158
Twelve months ended March 31,
2024		1,186		$	1,172
2025		1,189			1,201
2026		1,089			1,126
2027		1,120			1,104
2028					1,135
Thereafter		3,966			3,395
Total lease payments		9,708			9,133
Less imputed interest		(3,955	)		(3,565	)
Total operating lease liabilities	$	5,753		$	5,568

At ~~September 30, 2022,~~March 31, 2023, the weighted average remaining lease term was ~~8.0~~ 7.5years, and the weighted average discount rate was 14.1%. Total lease cost was $~~368~~480 and $~~1,341~~488 for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022, ~~respectively,~~respectively.

(16) Subsequent event

The Company is party to an amended License and $~~161~~Supply Agreement with Lannett Company, Inc. (“Lannett”). In May 2023, Lannett announced that it had entered into a restructuring support agreement with certain of its lenders and $~~347~~that it had commenced Chapter 11 cases and filed a prepackaged plan of reorganization in the United States Bankruptcy Court for the ~~three~~District of Delaware. As part of the announcement, Lannett stated that it will continue to operate in the ordinary course of business during the bankruptcy process and ~~nine~~that the Chapter 11 cases and prepackaged plan of reorganization, which are subject to court approval, provide for vendors to be paid in the normal course of business for obligations incurred prior to and subsequent to the commenced bankruptcy. At this time, Lannett continues to perform under the terms of the amended License and Supply Agreement, which generated 17% of the Company’s revenue in the three months ended ~~September 30, 2021, respectively.~~March 31, 2023, 19% of accounts receivable at March 31, 2023 (all of which were subsequently collected on May 8, 2023) and 27% of contract assets at March 31, 2023. As of March 31, 2023, no allowances for credit losses or other provisions for losses have been recognized based on Lannett’s stated intent to continue to operate in the ordinary course of business.

Item 2. Management’s discussion and analysis of financial condition and results of operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and notes thereto in Part I, Item 1 of this Quarterly Report on Form 10-Q, or Quarterly Report, and the audited consolidated financial statements and notes thereto for the year ended December 31, ~~2021~~2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the SEC on March 1, ~~2022,~~2023, or Annual Report.

In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions and other factors that could cause actual results to differ materially from those made, projected or implied in the forward-looking statements. Our actual results may differ materially from those discussed below. Please see “Forward-Looking Statements” and “Risk Factors” included in Part I, Item 1A of our Annual Report for factors that could cause or contribute to such differences.

Cautionary note regarding forward-looking statements

This Quarterly Report and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report or the documents incorporated by reference herein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” “could,” “should,” “potential,” “seek,” “evaluate,” “pursue,” “continue,” “design,” “impact,” “affect,” “forecast,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.

The forward-looking statements in this Quarterly Report and the documents incorporated herein by reference include, among other things, statements about:

•

our estimates regarding expenses, future revenue, cash flow, capital requirements and timing and availability of and the need for additional financing;

•

our ability to maintain or expand our relationships, profitability and contracts with our key commercial partners, including the impact of changes in consumer demand for the products we manufacture for our commercial partners;

•

our ability to grow and diversify our business with new customers, including our ability to meet desired project outcomes with development customers, and the potential loss of development customers if they do not receive adequate funding or if their products do not obtain U.S. Food and Drug Administration, or FDA, approval;

•

the extent to which ~~the ongoing COVID-19 pandemic~~health epidemics and other outbreaks of communicable diseases, continue to disrupt our business operations and the financial condition of our customers and suppliers, including our ability to initiate and continue relationships with manufacturers and third-party logistics providers given recent supply chain challenges;

•

~~the extent to which~~ inflation, geopolitical turmoil, social unrest, global instability, including political instability and any resulting sanctions, terrorism, or other acts of war, supply chain disruptions, trade restrictions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities may disrupt our business operations or our financial condition or the financial condition of our customers and ~~suppliers;~~suppliers, including our ability to initiate and continue relationships with manufacturers and third-party logistics providers;

•

our ability to operate under ~~increased leverage~~the lending covenants under our credit agreement and ~~associated lending covenants;~~ to pay ~~existing~~ required interest and principal amortization payments when due; ~~and/or to obtain acceptable refinancing alternatives;~~

•

the performance of third-party suppliers upon which we depend for Active Pharmaceutical Ingredients, or APIs, various other direct and indirect materials, and other third parties involved with maintenance of our facilities and equipment;

•

our ability to maintain and defend our intellectual property rights against third-parties;

•

pharmaceutical industry market forces that may impact our commercial customers’ success and continued demand for the products we produce for those customers;

•

our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers, including as a result of applicable state and federal vaccine mandates;

•

our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP, compliance and U.S. Drug Enforcement Agency, or DEA, compliance and other relevant regulatory authorities applicable to our business; and

•

our ability to realize the expected benefits of the IriSys, LLC, or IriSys, acquisition.

We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report, particularly under “Item 1A. Risk Factors,” that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make. You should read this Quarterly Report and the documents that we incorporate by reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements.

Solely for convenience, tradenames referred to in this Quarterly Report appear without the ® symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these tradenames. All trademarks, service marks and tradenames included or incorporated by reference in this Quarterly Report are the property of their respective owners.

Overview

Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization, or CDMO, with capabilities spanning pre-investigational new drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus ~~in the area of~~on small molecules. With an expertise in solving complex ~~formulation and~~ manufacturing problems, ~~we are~~Societal is a leading CDMO providing development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. In addition to our experience in handling DEA-controlled substances and developing and manufacturing ~~advanced~~modified-release dosage forms, ~~we have~~Societal has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our ~~best-in-class~~state-of-the-art facilities that, in the aggregate, total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

We currently manufacture the following key products with our key commercial partners: Ritalin LA®, Focalin XR®, Verelan PM®, Verelan SR®, Verapamil PM, Verapamil SR and Donnatal liquids and ~~tablets,~~tablets. We also support numerous development stage products. During the first quarter of 2023, the FDA approved the Company as a manufacturer of a commercial tablet product. This FDA approval represents the first commercial tablet that Societal CDMO has been approved to manufacture, and the Company expects to begin commercial manufacturing of the product at its Gainesville, Georgia facilities later this year.

Our manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle high potent compounds and controlled substances, liposomes and nano/microparticles, topicals and oral liquids. In September 2022, Societal announced a new state-of-the-art, aseptic fill/finish and lyophilization suite in our San Diego facility to further our goal of offering end-to-end solutions to our clients. In addition to providing manufacturing capabilities, we offer our customers clinical trial support including over-encapsulation, comparator sourcing, packaging, labeling, storage and distribution. We have a bi-coastal footprint from which to better serve clients within the U.S., as well as ~~supporting numerous development stage products.~~

~~Effective March 21, 2022,~~globally. In a typical collaboration between us and our commercial partners, we ~~changed~~continue to work with our ~~name~~partners to ~~Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a result~~develop product candidates or new formulations of ~~our acquisition~~existing product candidates. We also typically exclusively manufacture and ~~successful integration~~supply clinical and commercial supplies of ~~IriSys into the organization.~~these proprietary products and product candidates.

We use cash flow generated by our business primarily to fund the growth of our CDMO business and to make payments under our credit facility. We believe our business will continue to contribute cash to fund our growth, to make payments under our credit facility and for other general corporate purposes.

Global economic and supply conditions

Global economic conditions, logistics and supply chain issues continue to present obstacles to our ~~business despite having endured other challenges related to the COVID-19 pandemic during 2021.~~business.

We rely on third-party manufacturers to supply our manufacturing components, supplies and related materials, which in some instances are supplied from a single source. Prolonged disruptions in the supply of any of our third-party materials, difficulty implementing new sources of supply or significant price increases could have an adverse effect on our results. ~~While the impact of COVID-19 has lessened in many ways, we~~We are experiencing a higher level of residual supply chain disruptions that we are actively managing to meet our ~~fourth quarter 2022~~ production timelines and that may constrain our ability to capture additional growth opportunities, beyond our established projections, from customers who would otherwise want to increase their safety stock of the products that we produce.

We also continue to closely monitor global economic developments ~~related to COVID-19 and other diseases~~ and geopolitical conflicts, such as the conflict between Russia and Ukraine, which continue to have adverse effects on the U.S. and global ~~markets.~~markets and supply chain.

We continue to anticipate a general slowdown in clinical development activity as a result of clinical failures and/or a lack of adequate funding to go ~~forward, which~~forward. We are making efforts to adapt to these market changes, including a reconfiguration of our business development team to be better positioned in the longer-term by focusing on account management roles and replacing lost positions in strategic focus areas. The anticipated slowdown and/or the reconfiguration may cause a reduction in the number of business development opportunities that we will be able to pursue ~~during the remainder of 2022.~~in 2023. We also expect to face continuing inflationary pressures on raw materials, labor and logistics during ~~2022.~~2023. Finally, we were impacted by higher variable base interest rates on our ~~LIBOR-based term loan~~ borrowings under credit agreements during the ~~third quarter~~second half of 2022, and while we believe that we have been able to capture overall interest savings as a result of the December 2022 refinancing, we expect tothose improvements could be ~~further impacted during the fourth quarter of~~partially offset by that sustained variable base interest rate increases from 2022.

Financial overview

Revenues

We recognize three types of revenue: manufacturing, profit-sharing and ~~research~~development.

In May 2023, Lannett, which represented 16% of our revenue in 2022, commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware and ~~development.~~entered into a restructuring support agreement with certain of its lenders. At this time, we do not know how our agreement with Lannett will be treated in the bankruptcy case or how Lannett's performance with sales of Verapamil PM will impact our economics going forward.

Manufacturing

We recognize manufacturing revenue from the sale of products we manufacture for our commercial partners. Manufacturing revenues are recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration we expect to be entitled to as specified in the agreement with the commercial partner, which could include pricing and volume-based adjustments.

Profit-sharing

~~We recognize~~In addition to manufacturing revenue, certain customers who use our technologies are subject to agreements that provide us intellectual property sales-based profit-sharing and/or ~~royalty revenue,~~royalties consideration, collectively referred to as profit-sharing, ~~revenue, related to~~computed on the ~~sale~~net product sales of ~~products by our~~the commercial ~~partners that incorporate our technologies.~~partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. ~~For~~We have determined, that in our arrangements, ~~that include sales-based profit-sharing and~~ the license for intellectual property is ~~deemed to be~~not the predominant item to which the profit-sharing relates, so we recognize revenue when the related sales occur by the commercial partner. For arrangements that include sales-based profit-sharing and the license is not deemed to be the predominant item to which the profit-sharing relates, we recognize revenue when the performance obligation to which the profit-sharing has been allocated has been satisfied, which is upon transfer of control of ~~a product to a customer.~~the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by our commercial partners, which are outside of our control. Factors causing price adjustments by our commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing.

~~Research and development~~Development

~~Research and development~~Development revenue includes services associated with formulation, process development, clinical trial ~~material and clinical trial support~~materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms.

In contracts that specify milestones, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which we have continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within our control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received.

In contracts that require revenue recognition over time, we utilize input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications, and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request.

Cost of sales and selling, general and administrative expenses

Cost of sales consists of inventory costs, including production wages, material costs and overhead, and other costs related to the recognition of revenue. Selling, general and administrative expenses ~~consists~~consist of salaries and related costs for administrative, public company costs, business development personnel as well as legal, patent-related expenses and consulting fees. Public company costs include compliance, auditing services, tax services, insurance and investor relations.

In October 2021, we integrated and reorganized our collective employee base to support a multi-site organization. As a result, certain employees in administrative roles are supporting the entire company instead of plant operations. Costs associated with these employees, including employee compensation and other expenses, are classified in selling, general and administrative expenses prospectively from October 1, 2021.

Primarily in the last nine months of 2021, we qualified for approximately $4.4 million of federal employee retention credits that were recognized as offsets to expense. We will not recognize any such expense offsets in 2022.

Amortization of intangible assets

Historically, we recognized amortization expense related to an intangible asset for our profit-sharing and contract manufacturing relationships on a straight-line basis over an estimated useful life of six years. Amortization stopped when the intangible asset reached the end of its useful life in April 2021. With the acquisition of IriSys, weWe are recognizing amortization expense related to acquired customer relationships, backlog and trademarks and trade names on a straight-line basis over estimated useful lives of 7,7.0, 2.4, and 1.5 years, respectively.

Interest expense

Interest expense for the ~~periods~~current period presented primarily relates to our ~~Athyrium~~new term loan borrowing with Royal Bank of Canada of $36.9 million and the other liability related to the sale and leaseback of our commercial manufacturing campus in Gainesville, Georgia for gross proceeds of $39.0 million. Interest expense for the prior period presented primarily relates to the $100.0 million senior secured term loans with Athyrium Opportunities III Acquisition LP and the amortization of related financing costs. ~~In addition, following the acquisition~~

As a result of ~~IriSys, there is additional~~these changes, interest expense ~~related~~was lower in the first quarter of 2023 and will continue to be lower in future periods due to the lower amount of aggregate principal and lower variable interest onmargins as compared to the ~~sellers note which was a component of the IriSys acquisition purchase price.~~Athyrium borrowings.

Net operating losses and tax carryforwards

As of December 31, ~~2021,~~2022, we had federal net operating loss, or NOL, carry forwards of approximately ~~$135.9~~$125.6 million, ~~$127.7 million~~substantially all of which have an indefinite carry forward period. ~~The remaining $8.2 million of federal NOL carry forwards, $137.7~~We also had $135.4 million of state NOL carry forwards ~~and federal and state research and development tax credit carryforwards of $4.6 million are also~~ available to offset future taxable income ~~but they~~that will begin to expire at various dates beginning in 2028 if not utilized. We believe that it is more likely than not that ~~the~~our deferred income tax assets ~~associated with our U.S. operations~~ will not be realized, and as such, there is a full valuation ~~allowance against our U.S. deferred tax assets.~~allowance.

Key indicators of performance

To evaluate our performance, we monitor a number of industry-standard key indicators such as:

•

Safety and human capital management, as measured by recordable injuries, good saves and employee retention;

•

Operational excellence, as measured by the percentage of our orders that are delivered on-time and in full;

•

New business growth, as measured by value of new contracts signed; and

•

Financial operating results, as measured by revenue and EBITDA, as adjusted.

EBITDA, as adjusted, is a non-GAAP measure that we discuss and reconcile to its nearest GAAP measure elsewhere in our public financial reporting. We believe that supplementing our financial results presented in accordance with GAAP with non-GAAP measures is useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations ~~that provide a more complete~~and gaining an understanding of our business.

Results of operations

Comparison of ~~third quarters~~three months ended 2023 and 2022 ~~and 2021~~


	Three months ended September 30,						Three months ended March 31,
(in millions)	2022			2021			2023			2022
Revenue	$	21.6		$	18.2		$	21.5		$	21.2
Operating expenses:
Cost of sales (excluding amortization of intangible assets)		16.1			13.2
Cost of sales								19.3			16.2
Selling, general and administrative		5.1			4.6			4.6			5.7
Amortization of intangible assets		0.2			0.1			0.2			0.2
Total operating expenses		21.4			17.9			24.1			22.1
Operating income		0.2			0.3
Operating loss								(2.6	)		(0.9	)
Interest expense		(3.5	)		(3.8	)		(2.1	)		(3.4	)
Interest income								0.1			—
Loss before income taxes								(4.6	)		(4.3	)
Income tax expense								0.1			—
Net loss	$	(3.3	)	$	(3.5	)	$	(4.7	)	$	(4.3	)

Revenue. The increase of ~~$3.4~~$0.3 million was primarily driven by an increase in ~~European Ritalin LA demand from our new customer InfectoPharm,~~ revenue ~~resulting~~ from the acquisition of IriSys, as well as higher revenues from our clinical trial materials business. These increases were partially offset by declining revenues from Lannett’s commercial sales of Verapamil PM products compared to the prior year.

~~Cost of sales.~~ The increase of $2.9 million was primarily due to costs associated with operating the San Diego facility acquired from IriSys and increased costs tied to the increased manufacturing revenue during the quarter. In addition, in 2021, we received certain employment incentive tax credits that were not repeated in 2022 resulting in increased expense in 2022. These increases were partially offset by the reallocation of expenses reflecting the post-acquisition organizational structure. Prior to October 1, 2021, these employees supported our plant operations and were classified in cost of sales.

~~Selling, general and administrative.~~ The increase of $0.5 million was primarily related to increased personnel costs tied to the reallocation of expenses reflecting the post-acquisition organizational structure (see cost of sales above) and integration costs associated with the IriSys integration.

~~Amortization of intangible assets.~~ The increase of $0.1 million was the result of recognizing a full period of amortization on the acquired intangible assets of IriSys during the third quarter of 2022 as compared to a partial period in third quarter 2021.

~~Interest expense.~~ The decrease of $0.3 million was primarily due to increased capitalized interest and the extension of the maturity date of our term loans, which deferred some of the non-cash amortization of financing expenses to future periods. These decreases were partially offset by an increase in the variable LIBOR component of interest on our term loans.

~~Comparison of nine months ended 2022 and 2021~~

Nine months ended September 30,

(in millions)
2022

2021

Revenue
$
65.9

$
53.1

Operating expenses:

Cost of sales (excluding amortization of intangible assets)

49.6

39.8

Selling, general and administrative

15.9

13.1

Amortization of intangible assets

0.7

0.9

Total operating expenses

66.2

53.8

Operating loss

(0.3
)

(0.7
)
Interest expense

(10.4
)

(11.7
)
Gain on extinguishment of debt

—

3.4

Net loss
$
(10.7
)

$
(9.0
)

~~Revenue.~~ The increase of $12.8 million was primarily driven by revenue resulting from the acquisition of IriSys as well as higher revenues from our clinical trial materials business. In addition, there was an increase in European Ritalin LA demand from our new customer InfectoPharm as well as an increase in revenue from ourcompany’s largest commercial customer Teva, correlated with pull through in demand resulting from market share gains against the sole competitor for the Verapamil SR ~~products. The increase in revenue was~~products, partially offset by ~~a decline in revenue~~lower revenues from ~~Lannett’s commercial~~product sales to Lannett due to timing of ~~the Verapamil PM products.~~customer orders.

Cost of sales. The increase of ~~$9.8~~$3.1 million was primarily due to mix of revenue and related cost absorption, including increased costs associated with the ~~acquisition of the San Diego facility~~new aseptic fill/finish line as we expand capabilities and ~~certain 2021 employment incentive tax credits that were not repeated in 2022 resulting in~~ increased expense in 2022. These increases were partially offset by the reallocation of expenses reflecting the post-acquisition organizational structure. Prior to October 1, 2021, these employees supported our plant operations and were classified in cost of sales.material costs.

Selling, general and administrative. The ~~increase~~decrease of ~~$2.8~~$1.1 million was primarily related to ~~increased personnel~~lower public company costs ~~tied to~~and administrative costs than the ~~reallocation of expenses and integration costs associated with the IriSys integration. These increases were offset by lower IriSys acquisition expenses and lower stock-based compensation expense.~~prior year.

Amortization of intangible assets. The ~~decrease of $0.2 million was the result of the amortization of CDMO royalties and contract manufacturing relationships acquired in 2015 ending on April 10, 2021 partially offset by the~~ amortization related to the acquisition of IriSys for acquired customer relationships, backlog and trademarks and trade names.

Interest expense. The decrease of $1.3 million was primarily due to ~~the extension~~a significantly reduced amount of ~~the maturity date of our term loans, which deferred some of the non-cash amortization of financing expenses to future periods,~~aggregate principal and ~~increased capitalized interest. These decreases were partially offset by a full period of~~lower interest ~~on the debt portion of the IriSys acquisition purchase price and an increase in the variable LIBOR component of interest on our term loans.~~

~~Gain on extinguishment of debt.~~ ~~In June 2021, the promissory note with PNC Bank~~rates under the ~~Paycheck Protection Program of~~company's refinanced debt as compared to the ~~Coronavirus Aid, Relief and Economic Security Act of 2020, or~~borrowings outstanding during the ~~PPP Note, and all accrued interest thereon was forgiven.~~period ended March 31, 2022.

Liquidity and capital resources

At ~~September 30, 2022,~~March 31, 2023, we had ~~$11.6~~$6.3 million in cash and cash equivalents.

Since our inception, we have financed our operations and capital expenditures primarily from results of operations, ~~and~~from the issuance of equity and ~~debt.~~debt, and recently, to a lesser extent, from real estate transactions. During the first ~~nine months~~quarter of ~~2022,~~2023, our capital expenditures were ~~$5.6~~$3.4 million to scale and support our expansion of capabilities.

We are currently party to a credit agreement with ~~Athyrium,~~Royal Bank of Canada, or the Credit Agreement, ~~which has been fully drawn.~~for a term loan with a principal amount of $36.9 million. The ~~Credit Agreement requires us to repay the~~ outstanding principal amount will be repaid in quarterly amounts totaling $2.1 million, $3.0 million and $1.8 million during the twelve months ending March 31, 2024, 2025 and 2026, respectively. The final payment of ~~$100.0 million~~all remaining outstanding principal is due on December ~~31, 2023.~~ 16, 2025. If the Company completes a sale of certain real property by December 14, 2023, and makes the $10.0 million principal repayment disclosed below, the quarterly principal payments will be reduced proportionately to the reduction in principal.

Subject to certain exceptions, we are required to make mandatory prepayments with the cash proceeds received in respect of asset sales, extraordinary receipts and debt issuances, upon a change of control and specified other events. Additionally, we are obligated to repay $10.0 million of principal by December 14, 2023, upon the sale of certain real property adjacent to our Gainesville, Georgia manufacturing campus. If that property is not sold by December 14, 2023, we will be required to pay a fee of $0.4 million and increase each of our quarterly principal payments by $0.2 million until that property is sold and the $10,000 principal payment is made.

The Credit Agreement also includes certain financial covenants that the Company will need to satisfy on a ~~monthly and~~ quarterly basis, including: (i) maintaining a ~~permitted~~ net leverage ratio ~~calculated as our indebtedness, net~~less than 3.75:1.00, stepping down to 2.75:1.00 at the end of ~~cash~~2023; (ii) maintaining a fixed charge coverage ratio greater than 1.15:1.00; and ~~cash equivalents, divided by EBITDA, each as defined in the Credit Agreement; and (ii) a minimum amount of~~(iii) maintaining no less than $4.0 million cash and cash equivalents on ~~hand.~~

We are also party to an amended common stock purchase agreement with Aspire Capital Fund LLC, or Aspire Capital. The amended agreement provides that, upon the terms and subject to the conditions and limitations set forth in the agreement, Aspire Capital is committed to purchase, at our sole election,hand, stepping up to ~~an aggregate value~~$5.0 million by the end of $41.2 million in shares of common stock. As of September 30, 2022, there is availability to issue up to $30.0 million or 6,199,299 shares of common stock under the 2019 Common Stock Purchase Agreement.2024.

In September 2022, we signed a sales and purchase agreement to sell approximately 121 acres of land adjacent to our Gainesville, Georgia manufacturing campus for expected proceeds of $9.1 million, which we ~~intend~~are obligated to use to repay outstanding ~~term loan indebtedness.~~balances on the Credit Agreement. The land sale is expected to close in the second half of 2023. Until closing, the sale of the land is subject to customary closing conditions for transactions of this type, including completion of title and environmental due diligence and receipt of certain zoning approvals and permits.

We may require additional financing or choose to refinance certain of these instruments, which could include ~~debt refinancing, sale of real estate and/or other assets,~~ strategic development, licensing activities and/or marketing arrangements, ~~or through~~ public or private sales of equity or debt securities ~~from time to time.~~or debt refinancing. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. If and until we are able to obtain shareholder approval to increase the number of shares of common stock authorized under our articles of incorporation, we will be limited in the number of additional shares we will be able to issue in future periods. Further, our ability to access capital market or otherwise raise capital may be adversely impacted by potential worsening global economic conditions ~~geopolitical conflicts,~~ and the recent disruptions to, and volatility in, financial markets in the United States and worldwide, ~~resulting from~~including as a result of diseases, geopolitical conflicts, recent liquidity constraints or failures and instability in U.S. and international financial banking systems on the ~~ongoing COVID-19 pandemic and the conflict between Russia and Ukraine.~~global financial markets. Additional debt or equity financing, if available, may be dilutive to the holders of our common stock and may involve significant cash payment obligations and covenants that restrict our ability to operate our business or to access ~~capital.~~capital, and may further restrict dividend payments.

Sources and uses of cash


	Nine months ended September 30,						Three months ended March 31,
(amounts in millions)	2022			2021			2023			2022
Net cash (used in) provided by:
Net cash used in:
Operating activities	$	(5.6	)	$	6.4		$	(2.9	)	$	(8.1	)
Investing activities		(5.6	)		(26.8	)		(3.4	)		(1.7	)
Financing activities		(2.4	)		20.1			(2.5	)		(0.1	)
Total	$	(13.6	)	$	(0.3	)	$	(8.8	)	$	(9.9	)

~~Net cash used in operating activities in 2022 changed from net cash provided~~Cash flows from operating activities ~~during 2021, a decrease~~represents our net loss as adjusted for stock-based compensation expense, non-cash interest expense, depreciation expense, amortization of ~~$12.0 million. The decrease was primarily due to~~intangible assets and deferred income tax expense as well as changes in operating assets and liabilities. ~~These included (i) a $4.5~~The $5.2 million ~~change~~decrease in ~~accrued payroll~~cash flows used for operating activities in 2023 compared to 2022 was primarily due to ~~limited cash bonuses paid~~favorable working capital changes, partially offset by a decrease in ~~2021 and the timing~~earnings exclusive of month-end payroll payments; (ii) a $3.4 million change in inventory balances due to timing of production and customer orders; (iii) a $1.4 million change in accounts receivable due to the later timing of customer payments in 2022; and (iv) an additional $2.2 million interest payment that fell in the first quarter of 2022 compared to 2021.non-cash items.

Net cash used in investing activities for each period includes capital expenditures to scale and support our expansion of capabilities and included $24.0 million paid to acquire IriSys in 2021. With the inclusion of IriSys, 2022 capital expenditures have increased as we continue to maintain our existing capabilities and support the growth of our clinical trials business and other new business acquired from IriSys. We completed a significant capital project during the third quarter of 2022 that has enhanced our sterile fill and finishing capabilities.

Net cash used in financing activities ~~in 2022 changed from net cash provided by financing activities in 2021, a decrease of $22.5 million. The decrease was~~increased $2.4 million primarily due to ~~the absence of significant activities that occurred in 2021; net proceeds from an issuance of common stock of $32.1 million were partially offset by~~ debt repayments of ~~$10.1~~$0.5 million and ~~related financing cost~~ payments of ~~$1.4 million. That decrease was partially offset by a $2.0~~$1.8 million ~~scheduled repayment of principal under~~related to the ~~note with the former equity holder of IriSys.~~December 2022 debt refinancing.

Forward-looking factors

Our future use of operating cash and capital requirements will depend on many forward-looking factors, including the following:

•

the extent to which we in-license, acquire or invest in products, businesses and technologies;

•

the timing and extent of our manufacturing and capital expenditures;

•

our ability to maintain or expand our relationships and contracts with our commercial partners;

•

our ability to grow and diversify our business with new customers, including our ability to meet desired project outcomes with development customers;

•

our ability to regain profitability;

•

our ability to comply with stringent U.S. & foreign government regulation in the manufacture of pharmaceutical products, including cGMP and ~~U.S.~~ DEA requirements;

•

our ability to raise additional funds through equity or debt financings or sale of real estate or other assets;

•

the costs of maintaining, enforcing and defending intellectual property claims; and

•

the extent to which health epidemics and other outbreaks of communicable diseases, ~~including the ongoing COVID-19 pandemic, could disrupt our operations or materially and adversely affect our business and financial conditions; and~~

•

~~the extent to which~~ inflation, global instability, including political instability and any resulting sanctions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities may disrupt our business operations or financial condition or the financial condition of our customers and suppliers.

We anticipate raising funds from real estate asset sales to reduce our outstanding debt principal. There are a number of risks and uncertainties that could impact real estate values and or our ability, if any, to successfully monetize the sale of any non-core real-estate assets including, but not limited to, market forces, economic conditions, revenue concentration, debt levels, geographic location, interest rates, results of engineering plans, geotechnical surveys, coverage density, physical characteristics of the land (e.g. rock, wetlands delineation, streams, powerlines, topography, zoning), ability to reach acceptable contractual terms and obtaining the required approvals and release(s) from our senior secured lender.

We may ~~also~~ use existing cash and cash equivalents on hand, additional debt, equity financing, sale of real-estate or other assets or out-licensing revenue or a combination thereof to fund our operations or acquisitions. If we increase our debt levels, we might be restricted in our ability to raise additional capital and might be subject to financial and restrictive covenants. ~~Our~~If and until we are able to obtain shareholder approval to increase the number of shares of common stock authorized under our articles of incorporation, we will be limited in the number of additional shares we will be able to issue in future periods. If we do issue additional equity in future periods, our shareholders may experience ~~dilution as a result of the issuance of additional equity or debt securities.~~dilution. This dilution may be significant depending upon the amount of equity or debt securities that we issue and the prices at which we issue any securities.

Contractual commitments

The table below reflects our contractual commitments as of ~~September 30, 2022:~~March 31, 2023:


	Payments due by period										Payments due by period
(in millions)	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years		Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Debt obligations (1):
Principal	$	104.5	$	2.0	$	102.1	$	0.1	$	0.3	$	40.8	$	7.8	$	32.7	$	0.1	$	0.2
Interest		12.5		9.7		2.6		0.1		0.1		9.2		3.5		5.6		0.1		—
Purchase obligations (2)		12.4		11.8		0.6		—		—		9.9		9.5		0.4		—		—
Operating leases (3)		9.7		1.2		2.4		2.2		3.9		9.1		1.2		2.3		2.2		3.4
Other long-term liabilities ~~(4)~~(5)		—		—		—		—		—		93.6		3.5		7.4		7.9		74.8
Total	$	139.1	$	24.7	$	107.7	$	2.4	$	4.3	$	162.6	$	25.5	$	48.4	$	10.3	$	78.4

(1)

Debt obligations consist of principal ~~an exit fee of 1% of that principal,~~ and interest on ~~$100.0~~$36.4 million of an outstanding term ~~loans~~loan under our credit facility with ~~Athyrium,~~Royal Bank of Canada, $4.1 million of notes issued to the former members of IriSys and ~~another~~a small ~~loan.~~finance lease. Because the ~~Athyrium~~Royal Bank of Canada term ~~loans bear~~loan bears interest at a variable rate based on ~~LIBOR,~~SOFR, we estimated future interest commitments utilizing the ~~LIBOR~~SOFR rate as of ~~September 30, 2022.~~March 31, 2023. In accordance with U.S. GAAP, the future interest obligations are not recorded on our consolidated balance sheet.

(2)

Purchase obligations consist of cancelable and non-cancelable purchase commitments related to inventory, capital expenditures and other goods or services. In accordance with U.S. GAAP, these obligations are not recorded on our consolidated balance sheets.

(3)

We are party to two operating leases for development facilities in California and Georgia that end in 2031 and 2025, respectively. The leases each include options to extend at our discretion.

(4)

We are party to a lease for a DEA-licensed facility in Georgia that ends in 2042. The lease includes the option to extend at our discretion. The principal component of this obligation is classified as a liability under U.S. GAAP, therefore we did not present it as an operating or capital lease in the table.

(5)

We have entered into employment agreements with each of our ~~named~~ executive officers that provide for, among other things, severance commitments of up to ~~$1.3~~$1.4 million should we terminate the ~~named~~ executive officers for convenience or if certain events occur following a change in control. In addition, we would be subject to other contingencies of up to ~~$3.8~~$3.9 million in the aggregate if certain events occur following a change in control. Because these obligations are contingent, the amounts are not included in the table above.

Critical accounting policies and estimates

Our critical accounting policies and estimates are disclosed in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report.

Item 3. Quantitative and qualitative disclosures about market risk

There has been no material change in our assessment of our sensitivity to market risk described in the Annual Report.

Item 4. Controls and procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of ~~September 30, 2022.~~March 31, 2023. We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure.

A control system, no matter how well conceived and operated, can provide only reasonable, and not absolute, assurance that the objectives of the control system will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. However, our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of ~~September 30, 2022,~~March 31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in internal control over financial reporting

There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal proceedings.

Information regarding legal and regulatory proceedings is set forth in note 7 to our consolidated financial statements included in Part I, Item 1 of this Quarterly Report, and is incorporated by reference herein.

We are also engaged in various other legal actions arising in the ordinary course of our business (such as, for example, proceedings relating to employment matters or the initiation or defense of proceedings relating to intellectual property rights) and, while there can be no assurance, we believe that the ultimate outcome of these other legal actions will not have a material adverse effect on our business, results of operations, financial condition or cash flows.

Item 1A. Risk factors.

Investing in our securities involves certain risks. In addition to any risks and uncertainties described elsewhere in this Quarterly Report, investors should carefully consider the risks and uncertainties discussed in Part I, Item 1A. “Risk Factors” in our Annual Report. These risks are not the only risks that could materialize. Other than as set forth below, there have been no material changes in our risk factors from those previously disclosed in our ~~2021~~ Annual ~~Report, Quarterly Report~~Report.

Our revenues are dependent on a small number of commercial partners, and the loss of any one of these partners, or a decline in their orders, may adversely affect our business.

We are dependent on a small number of commercial partners, with our four largest customers (Teva Pharmaceutical Industries, Inc., or Teva, Novartis Pharma AG, or Novartis, Lannett Company, Inc., or Lannett, and InfectoPharm Arzneimittel und Consilium GmbH, or InfectoPharm) having generated 77% of our revenues for the ~~quarter~~year ended ~~March~~December 31, 2022, of which Teva generated 34%, Novartis generated 18%, Lannett generated 16%, and ~~Quarterly Report~~InfectoPharm generated 9%. In May 2023, Lannett commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the ~~quarter ended June 30, 2022.~~District of Delaware and entered into a restructuring support agreement with certain of its lenders. At this time, we do not know how our agreement with Lannett will be treated in the bankruptcy case, how our relationship with Lannett will be impacted going forward, and whether Lannett will continue to be able to satisfy its payment and other obligations to the Company. In addition, Novartis has provided us notice it intends to assign our agreement to Sandoz, its generic division, as part of the public spin-off of Sandoz. Such developments with Lannett and Novartis, as well as any increases in competition in the market, pricing adjustments, significantly reduced purchasing volume or financial difficulties (for example, the Lannett bankruptcy) with any one or more of our key commercial partners could adversely affect our revenue.

Our profit sharing, royalty, and manufacturing revenues also depend on the ability of our commercial partners to effectively market and sell their products to their customers. A commercial partner may choose to devote its efforts to its other products or reduce or fail to devote the necessary resources to provide effective sales and marketing support for the products we manufacture and supply. Furthermore, the acquisition of or change in strategy by one of our customers could impact projects we are currently working on or planning to work on in the future. Our commercial partners face competition from other pharmaceutical companies for sales of products to end users. Competition from sellers of generic drugs is a major challenge for our commercial partners, and the loss or expiration of intellectual property rights for the products we manufacture can have a significant adverse effect on their sales volume and price. Our commercial partners have also experienced difficulties in recent years as the pharmaceutical industry was impacted by the COVID-19 pandemic, labor shortages, supply chain shortages, inflationary pressures and geopolitical turmoil. Similar pressures could lead a partner to discontinue a product, make pricing changes or change ordering patterns. In addition, as pharmaceutical product pricing faces scrutiny by governments, legislative bodies and enforcement agencies, our commercial partners may lower their prices or adopt cost-savings measures which could be passed on to us or otherwise impact our profit-sharing revenues. Further, any commercial partner may divest the product we manufacture for them in whole or in certain markets, which may involve termination of our contract with such partner or the assignment of such contract to a new partner who may not be as effective at selling or commercializing such product. Pricing changes and any significant reduction, delay or cancellation of orders from our commercial partners could adversely affect our revenues.

Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.

Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Most recently, in March 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. Similarly, in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership, and in May 2023, First Republic was swept into receivership and its assets were sold to JPMorgan Chase. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.

In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.

Item 2. Unregistered sales of equity securities and use of proceeds.

None.

Item 3. Defaults upon senior securities.

None.

Item 4. Mine safety disclosures.

Not applicable.

Item 5. Other information.

~~None.~~On May 9, 2023, our Board approved and adopted the Fifth Amended and Restated Bylaws, or the Amended Bylaws. The amendments address matters relating to Rule 14a-19 under the Exchange Act, or the Universal Proxy Rules, providing, among other things, that:

•

a shareholder delivering a notice of nomination must include a representation that it intends to solicit proxies from shareholders representing at least 67% of the voting power of shares entitled to vote on the election of directors;

•

a shareholder delivering a notice of nomination must certify to the Company in writing that it has complied with the Universal Proxy Rules requirements;

•

the Company may disqualify a shareholder’s nomination if such stockholder fails to satisfy the Universal Proxy Rules requirements;

•

a shareholder providing notice pursuant to the Company’s advance notice bylaws must inform the Company if the shareholder no longer plans to solicit proxies in accordance with the Universal Proxy Rules; and

•

the shareholder will use a proxy card color other than white, which is reserved for the exclusive use of the Board.

The above description of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Fifth Amended and Restated Bylaws, which is filed as Exhibit 3.1 hereto and incorporated herein by reference.

Item 6. Exhibits.

(a)

The following exhibits are filed herewith or incorporated by reference herein:

EXHIBIT INDEX


Exhibit No.	Description	Method of filing
3.1	Fifth Amended and Restated Bylaws of Societal CDMO, Inc.	Filed herewith
4.1	Common Stock Purchase Warrant in favor of OTA LLC (as assigned by Athyrium)	Filed herewith
10.1	First Amendment ~~No. 3~~ to ~~License and Supply~~Credit Agreement dated as of ~~July 1, 2022~~April 4, 2023, by ~~and among~~ Societal CDMO, ~~Gainesville LLC and Lannett Company,~~ Inc. in favor of Royal Bank of Canada	~~Incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 10, 2022~~
~~10.2~~	Purchase and Sale Agreement and Joint Escrow Instructions dated August 11, 2022, by and among Societal CDMO Gainesville, LLC, a Massachusetts limited liability company and Weekley Homes, LLC, a Delaware limited liability company.	~~Incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 16, 2022~~Filed herewith
31.1	Rule 13a-14(a)/15d-14(a) certification of Principal Executive Officer	Filed herewith
31.2	Rule 13a-14(a)/15d-14(a) certification of Principal Financial and Accounting Officer	Filed herewith
32.1	Section 1350 certification, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101 INS	XBRL Instance Document	Filed herewith
101 SCH	XBRL Taxonomy Extension Schema	Filed herewith
101 CAL	XBRL Taxonomy Extension Calculation Linkbase	Filed herewith
101 DEF	XBRL Taxonomy Extension Definition Linkbase	Filed herewith
101 LAB	XBRL Taxonomy Extension Label Linkbase	Filed herewith
101 PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	SOCIETAL CDMO, INC.

Date: ~~November 9, 2022~~May 10, 2023	By:	/s/ J. David Enloe, Jr.
		J. David Enloe, Jr.
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: ~~November 9, 2022~~May 10, 2023	By:	/s/ Ryan D. Lake
		Ryan D. Lake
		Chief Financial Officer
		(Principal Financial and Accounting Officer)


	Date or period	Shares of common stock issued		Gross proceeds		Offering expenses			Net proceeds
Initial public offering	March 12, 2014		4,312,500	$	34,500	$	(4,244	)	$	30,256
Private placement	July 7, 2015		1,379,311		16,000		(1,188	)		14,812
Underwritten public offering	August 19, 2016		1,986,666		14,900		(1,533	)		13,367
Underwritten public offering	December 16, 2016		6,670,000		40,020		(3,132	)		36,888
2018 common stock purchase agreement with Aspire Capital	Year ended December 31, 2018		1,950,000		16,999		—			16,999
2019 common stock purchase agreement with Aspire Capital	Fourth quarter 2020		4,690,972		11,172		(78	)		11,094
Share issuance agreement for amendment 5 to Credit Agreement	February 2021		2,202,420		9,338		(20	)		9,318
Underwritten public offering	May 12, 2021		15,333,332		34,500		(2,397	)		32,103
Issuance of shares for IriSys acquisition	February 2022		9,302,718		20,931		(619	)		20,312


	Contract assets			Contract liabilities
Balance at December 31, 2021	$	8,565		$	2,308
Changes to the beginning balance of contract assets arising from:
Reclassification to receivables as a result of rights to consideration becoming unconditional		(11,224	)		—
Reduction to offset within net contract asset due to recognition of revenue		1,017			—
Changes in estimate		1,659			—
Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates		9,395			—
Changes to contract liabilities:
Amounts billed in advance of contract performance		—			4,921
Revenue recognized		—			(4,857	)
Balance at September 30, 2022	$	9,412		$	2,372